| 10 0 (0%) | 04-03 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 11.68 |
1-year : | 13.64 |
| Resists | First : | 10 |
Second : | 11.68 |
| Pivot price | 9.91 |
|||
| Supports | First : | 9.9 |
Second : | 9.85 |
| MAs | MA(5) : | 9.93 |
MA(20) : | 9.91 |
| MA(100) : | 9.41 |
MA(250) : | 6.9 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 83.8 |
D(3) : | 77.3 |
| RSI | RSI(14): 65.9 |
|||
| 52-week | High : | 10.3 | Low : | 3.49 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ APEN ] has closed Bollinger Bands are 90.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 71 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 10.01 - 10.05 | 10.05 - 10.09 |
| Low: | 9.82 - 9.86 | 9.86 - 9.91 |
| Close: | 9.93 - 10 | 10 - 10.07 |
Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices. The company offers OverStitch and OverStitch Sx Endoscopic Suturing Systems that enable advanced endoscopic procedures by allowing physicians to sutures and secure the approximation of tissue through a flexible endoscope. It also provides Orbera, an intragastric balloon system that reduces stomach capacity causing patients to consume less following the procedure, as well as delays gastric content emptying under the Orbera Intragastric Balloon System, BIB, and Orbera365 Managed Weight Loss System brands. Additionally, the company offers X-Tack Endoscopic HeliX Tacking System, a suture-based device for closing and healing defects in the lower and upper gastrointestinal tract. The company sells its products to medical services providers; and hospitals, outpatient surgical centers, clinics, and physicians in the United States, Australia, Costa Rica, and other European countries. Apollo Endosurgery, Inc. was founded in 2005 and is headquartered in Austin, Texas.
Mon, 20 Jan 2025
Apollo Endosurgery to be Acquired by Boston Scientific - ACCESS Newswire
Tue, 04 Apr 2023
Boston Scientific completes Apollo Endosurgery acquisition - MassDevice
Wed, 30 Nov 2022
Boston Scientific shelling out $615M for Apollo Endosurgery - The Business Journals
Wed, 30 Nov 2022
Why Boston Scientific (BSX) Is Buying Apollo Endosurgery (APEN) For $615 Million In Cash - Pulse 2.0
Tue, 29 Nov 2022
Buy-rated Boston Scientific's $615 million takeover of Apollo Endosurgery is a positive, says Needham - MarketWatch
Tue, 29 Nov 2022
Why is Apollo Endosurgery, Inc. (APEN) stock gaining traction today? - Kalkine Media
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 48 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 5.2 (%) |
| Held by Institutions | 77.2 (%) |
| Shares Short | 462 (K) |
| Shares Short P.Month | 566 (K) |
| EPS | -1.05 |
| EPS Est Next Qtrly | -0.38 |
| EPS Est This Year | -2.07 |
| EPS Est Next Year | -1.3 |
| Book Value (p.s.) | 1.01 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.89 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -9.53 |
| PEG Ratio | 0 |
| Price to Book value | 9.8 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | 2016-12-29 |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|